Oxazole/1,2,3-triazole isosteric replacement Ynamide CuACC Click chemistry VEGFR2 tyrosine kinase inhibition Cytotoxic activity in Huh-7 and Mahlavu hepatocellular carcinoma cell lines PI3K/Akt pathway a b s t r a c t Structure novelty, chemical stability and synthetic feasibility attracted us to design 1,2,3-triazole compounds as potential inhibitors of VEGFR2 tyrosine kinase. Novel triazoles T1eT7 were proposed by oxazole (AAZ from PDB: 1Y6A)/1,2,3-triazole isosteric replacement, molecular modelling and docking. In order to enable synthesis of T1eT7 we developed a methodology for preparation of ynamide 22. Compound 22 was used for all Click chemistry reactions leading to triazoles T1eT3 and T6eT7. Among the obtained products, T1, T3 and T7 specifically bind VEGFR2 TK and modulate its activity by concentration dependent manner. Moreover predicted binding poses of T1eT7 in VEGFR2 TK were similar to the one known for the oxazole inhibitor AAZ (PDB: 1Y6A). Unfortunately the VEGFR2 inhibition by triazoles e.g. T3 and T7 is lower than that determined for their oxazole bioisosters T3-ox and AAZ, resp. Different electronic properties of 1,2,3-triazole/oxazole heterocyclic rings were proposed to be the main reason for the diminished affinity of T1eT3, T6 and T7 to an oxazole AAZ inhibitor binding site in VEGFR2 TK (PDB: 1Y6A or 1Y6B). Moreover T1eT3 and T6 were screened on cytotoxic activity against two human hepatocellular carcinoma cell lines. Selective cytotoxic activity of T2 against aggressive Mahlavu cells has been discovered indicating possible affinity of T2 to Mahlavu constitutionally active PI3K/Akt pathway.
Introduction
Anti-angiogenesis agents that target malignant vasculature are of considerable interest due to their perceived potential to target tumour resistance towards chemo-and radiotherapy [1, 2] . Vascular endothelial growth factors (VEGFs) and their corresponding family of receptor tyrosine kinases (VEGFRs) are the key proteins modulating angiogenesis, the formation of new vasculature from an existing blood network. These include VEGFR1 (Flt1), VEGFR2 (Kinase Insert Domain Receptor (KDR) or Flk1). The last one, VEGFR3 is specialized for lymphagiogenesis [3] . VEGFR2 is the major positive signal transducer for endothelial cells proliferation and differentiation [4] . There has been considerable evidence, including clinical observations, that the abnormal angiogenesis is implicated in a number of diseases including rheumatoid arthritis, inflammation, degenerative eye conditions and cancer [5, 6] .
Cancer stem cells (CSCs) represent a small but the most tumourigenic subpopulation from the tumour cells responsible for metastasis, tumour recurrence and drug resistance. CSCs, also called "the roots of cancer", are considered to be a new promising therapeutic target [7] . VEGFR2 is regarded as an endothelial cell protein but evidences suggest that VEGFRs may be expressed also by cancer cells. Glioblastoma multiforme (GBM) is characterized by florid vascularisation and aberrantly elevated VEGF. Antiangiogenic therapy with bevacizumab reduces GBM tumour growth. VEGFR2 is expressed on CD133 þ human glioma cancer stem cells (GCSCs). VEGF-VEGFR2-Neuropilin1 (NRP1) axis influences GCSCs viability, self-renewal, and tumourigenicity. GCSCs viability was attenuated by direct inhibition of VEGFR2 TK activity and/or knockdown of VEGFR2 or NRP1. VEGFR2 inhibitors may block the VEGF-VEGFR2-NRP1 pathway [8, 9] . VEGF via VEGFR2 stimulates proliferation of glioblastoma multiform CSCs. VEGF stimulates GCSCs tumourigenesis and angiogenesis. Suppression of VEGFR2 signalling is therefore a potential therapeutic strategy in GBM [10] . VEGFR2 plays a key role in ability of glioblastoma CSCs to vasculogenic mimicry (VM) formation, neovascularisation and tumour initiation. Knockdown of VEGFR2 in GCSCs markedly reduced their selfrenewal, forming tubules, initiating xenograft tumours, promoting vascularisation and the establishment of VM. VEGFR2 is an essential molecule to sustain the "stemness" of GCSCs, their capacity to initiate tumour vasculature, and direct initiation of tumours [11] . Therefore VEGFR2 inhibitors are important compounds reducing angiogenesis and promising compounds to interfere with CSCs resistance.
The PDB database contains VEGFR2 TK complex 1Y6A possessing N-aryl-5-aryloxazol-2-amine ligand AAZ ( Fig. 1 ) determined as a powerful VEGFR2 inhibitor (IC 50 : 22 nM). Ligand AAZ was prepared in five steps in a low overall 10% yield mostly due to the problematic oxazole-2-amine fragment formation [12] . Low yields of oxazole-2-amine formation (1e58 %) have been also described [13, 14] . Moreover AAZ contains N-aryloxazol-2-amine part that uses to liberate from connection with oxazole by influence of nucleophilic reagent (e.g. amines, alkoxides etc.). Nucleophilic attack on C(2) of AAZ oxazole ring resulting in toxic aniline 26 (Scheme 1). (unpublished results) Low yielding synthesis of Naryloxazol-2-amines, their problematic stability and potential toxicity resulting from releasing aniline inspired us to develop novel, stable and synthetically more feasible VEGFR2 modulators based on the oxazole/1,2,3-triazole isosteric replacement. (Fig. 1 ) Replacing the heterocyclic ring in the structure of some inhibitors can provide a novel compounds with improved properties [15] .
1,4-Disubstituted 1,2,3-triazoles are stable compounds easily obtainable in high yields from organic alkynes and azides by Cu(I) catalyzed reaction (CuACC Click chemistry) [16] . Click reaction allows rapid preparation of different triazoles that is especially advantageous if one of the reactants is the same in all performed reactions (e.g. ynamide 22a in our case, Schemes 8 and 11). Additionally, Click reaction can selectively provide also 1,5-regioisomeric compounds via Ru (II) catalyzed cycloaddition [17] ( Fig. 1 ).
Only few active 1,2,3-triazole containing VEGFR2 TK inhibitors are described in the literature: 6 inhibitors 1e6 possessing IC 50 < 50 nM, (Fig. 2) 10 substances with IC 50 < 100 nM and 19 compounds having IC 50 200 nM [18] .
Imidazopyridazine 1 is the most active 1,2,3-triazole containing VEGFR2 inhibitor (IC 50 : 1.2 nM) [19] . Other active inhibitors are e.g. benzoxazolamine 2 (IC 50 : 8 nM) [20] , quinazolinamines 3 and 4 (IC 50 : 10 and 30 nM, resp.) [21, 22] , indazolurea 5 (IC 50 : 45 nM) [23] and ureidopyridine-N-oxide 6 (IC 50 : 49 nM) [24] . All of these VEGFR2 inhibitors (Fig. 2) possess a terminal 1,2,3-triazole fragment. In these cases, triazole group need not contribute to the inhibitor target affinity. Triazole group can be used to improve the ligand pharmacokinetic properties. E.g. the most potent inhibitor 1 (IC 50 : 1.2 nM) was designed by pyrazole/triazole isosteric replacement in the structure of ligand from PDB complex 3VO3. In case of PDB: 3VO3 a pyrazole ring does not bind the VEGFR2 TK directly. It is exposed towards the solvent accessible part of the protein [19] . Therefore triazole core that replaces a pyrazole ring can have the same position. Compound 7 is a close analogue of sunitinib that is an active base of the drug Sutent (Pfizer Inc.). Sunitinib inhibitory activity IC 50 ¼ 39 nM (VEGFR2 TK) was determined [25] . The structure 7 possesses N-1,2,3-triazolylethyl group instead of N,Ndiethylaminoethyl group present in sunitinib (Fig. 3) . Recently an X-ray structure of VEGFR2 TK/sunitinib complex (PDB: 4AGD) appeared [26] . From its analysis is clear that the N,N-diethylamino group in sunitinib is exposed out of the VEGFR2 protein and represents only a group improving the ligand pharmacokinetic profile.
Although X-ray structure of complex 7 with VEGFR2 kinase is not known, an analogous function can be expected also for the triazole group in 7 (Fig. 3) .
Only few VEGFR2 TK inhibitors possessing internal 1,2,3-triazole core were found in the literature. Compounds 8e10 were described as VEGFR2 activity modulators (K i > 915 nM (VEGFR2)) [27] . The staurosporin-like inhibitor 11 moderately influences the VEGFR2 kinase activity (IC 50 : 200 nM) [28] (Fig. 4) . Kiselyov et al. described the most active VEGFR2 inhibitors 12e14 (IC 50 : 51e87 nM) possessing an internal 1,2,3-triazole core [29] (Fig. 5) .
Our docking results proposed that the triazole fragment in 12e14 directly contributes the binding with VEGFR2 TK. The predicted intermolecular interactions of 12 and 14 are depicted on Fig. 6 . Moreover proposed positions of the above triazole inhibitors in VEGFR2 ATP active site is similar to the poses of ligands from PDB complexes 2P2I (IC 50 : 38 nM), and 3EFL (IC 50 : 3 nM). (not shown) Both VEGFR2 kinase conformers (PDB: 2P2I and 3EFL) used in docking experiments are VEGFR2 inactive (DFG-out) kinases originally accommodating Type II inhibitor [14] .
Considering the data mentioned above, we decided to prepare VEGFR2 TK modulators T1eT7 possessing an internal 1,2,3-triazole core and determine their VEGFR2 TK inhibition potential.
Results and discussion

Interaction analysis of AAZ conformers
Oxazole VEGFR2 TK inhibitor AAZ was developed by GlaxoSmithKline [12] . The intermolecular interactions for both AAZ conformers present in VEGFR2 TK complex PDB: 1Y6A are depicted on Fig. 7 .
Based on the above analysis, we decided to keep the pharmacophorically interesting 5-(ethylsulfonyl)-2-methoxyphenylamine fragment from AAZ ligand in all predicted triazole structures T1eT7. (Fig. 10) The proposed intermolecular interactions of triazoles T1eT7 and their poses in VEGFR2 kinase were similar to those known for AAZ ligand from PDB complex 1Y6A. (e.g. T3 from Fig. 12) . 
In Silico predictions
An interaction analyse, molecular modelling and docking were used to identify the skeletons of 1,2,3-triazole derivatives T1eT7. (Fig. 10) A reduced success of in Silico predictions is often associated with the ligand based target induced fit [30e32]. Therefore, for our docking experiments we selected the kinase variants of VEGFR2 from PDB complexes 1Y6A and 1Y6B possessing structurally the most relative oxazole ligands (AAZ and AAX, resp.). These ligands represent Type I, ATP competitive VEGFR2 inhibitors that bind to an exceptional inactive VEGFR2 tyrosine kinase possessing an opened activation loop as was discovered by us recently [14] . Because the structure similarity between AAZ (AAX) and proposed triazoles (e.g. T7, T6, T3 and T5) we did not expect strong influence of triazole ligand based induced fit. On the other hand, it was not easy to find triazole structures possessing AAZ-like score and pose by docking. The initial in Silico experiments were performed by an older DOCK software version with a kinase taken from PDB complex 1Y6B [33] . Some 1,4-disubstituted triazole skeletons that fulfilled both required score (AAZ: À53.6 kcal/mol) and pose conditions were selected: e.g. T3 (score À57.2), T5 (À52.9), T6 (À51.3), T2 (À51.3), T4 (À49.2). The triazole core of T1eT7 retains predicted hydrogen bond interaction with the kinase backbone amino acid residue Cys917 an important interaction known from AAZ oxazole ring in PDB: 1Y6A (Fig. 7) . Pharmacokinetic properties of triazoles T1 e T7 predicted by Molinspiration toolkit supported their drug-likeness [34e38] (see supporting material). Proposed properties for 1,4-regioisomeric triazoles T1eT7 were promising. Therefore we decided to perform their synthesis. 1,5-Regioisomeric triazole analogues ( Fig. 1 ) of T1eT7 were also docked by the same conditions. All these compounds were less advantageous possessing lower docking scores and several of them did not retain expected AAZlike pose in VEGFR2 TK. (not shown) Therefore 1,5-regioisomers were omitted.
For the synthesis of all 1,4-disubstituted 1,2,3-triazoles T1eT7 the pharmacophoric ynamide 22 (in modifications 22ae22d) was required. (Schemes 8, 9 and 11) Its synthesis was developed starting from aniline derivative 26. (Scheme 1).
Synthesis
In order to obtain compounds T1eT7 (Fig. 10) , we started synthesis their precursors azides 15e21 and ynamides 22ae22d (Fig. 8 ).
Preparation of ynamides 22a,b
Ynamides are stabilized equivalents of the corresponding reactive ynamines [39, 40] . Diminishing the electron-donating ability of ynamine nitrogen by its protection with an electron-withdrawing group (EWG) leads to more stable ynamides. Since the first synthesis of ynamides reported by Viehe in 1972 [41] , different methods have been published and the possible pathways towards required ynamides 22a,d are summarized in Scheme 1. Starting 5-(ethylsulfonyl)-2-methoxyaniline (26) was prepared from commercially available 4-methoxybenzenesulfonyl chloride according to a recently described procedure in four steps and 59% overall yield [42] .
CoreyeFuchs alkynylation proved to be ineffective in our hands. [52] significantly improved the yield of ynamides by using modified reaction conditions (0.20e0.30 eq of CuI, 0.22e0.36 eq of the 1,10-phenanthroline ligand and adding 1.20 eq of the base KHMDS slowly over 3e4 h in toluene at 90 C). In 2008, Skrydstrup et al. [53] published the Hsung's second generation protocol where potassium phosphate or carbonate was used as the mild base instead of KHMDS. In this case, anhydrous K 3 PO 4 provided higher ynamide yields (52e91%). The latter conditions brought positive results and ynamides 22a,b were prepared from carbamates 31a,b and alkyne bromide 29 in 94 and 59% yield respectively over two steps (Scheme 1, Path D and Scheme 3).
Preparation of azides 15e21
The synthesis of azides 15e19 and 21 was performed by a SuzukieMiyaura cross coupling conditions followed by an aromatic substitution (Scheme 4).
According to this strategy, azides 15, 16, 17 and 19 were prepared in 57 and 45% yield over two steps for 15 and 17, 33% over three steps for 16 and 37% yield over seven steps for 19 starting from pnitroaniline 37. (Scheme 5) Palladium catalyzed coupling of 2-bromopyridine with boronic acid 33 in the presence of sodium carbonate in a mixture of water/ethanol and DME at 75 C within 16 h [54] afforded biaryl bromide 34 which was treated with sodium azide and copper(I) iodide according to the procedure of Liang and co-workers to deliver azide 15 [55] . Subsequently a palladium-catalyzed acetoxylation of arene CeH bond at ortho position to the pyridine-2-yl substituent has been performed by phenyliodine diacetate (PhI(OAc) 2 ) in acetic anhydride [56] . These conditions led regioselectively to azide 16 in 57% yield. Biaryl bromide 36 was obtained from the SuzukieMiyaura cross coupling [54] between pinacolboronic ester 35 [57] and 1,3-dibromobenzene and converted to azide 17 using the Liang's protocol. (Scheme 5) Preparation of azide 19 started with ortho-iodination [58] of pnitroaniline 37, followed by protection of amino group of the resulting iodide 38 as acetamide 39 [59] and subsequent SuzukieMiyaura coupling with 1-naphtylboronic acid [60] to deliver biarylic compound 40 in 82% yield over three steps. The transformation of nitro derivative 40 to the corresponding azide 42 was performed in 2 steps via aniline 41 [61, 62] . Deacetylation of 42 was performed under basic conditions. Finally, urea derivative 19 was prepared from unstable amino azide 43 by trichloroacetyl isocyanate in dry dichloromethane followed by basic treatment [63] (Scheme 5).
Preparation of azides 18 and 21 following the same pathway proved to be unsuccessful with exception of 18b that was prepared in 44% yield over two steps (Scheme 6).
Biarylic bromophenols 46a,b were obtained by coupling reaction of pinacolboronic ester 35 with protected iodophenols 44a,b, prepared from para-bromoanisol respectively in one (98% yield) or three steps (87% overall yield), and subsequent deprotection of the resulted phenol ethers 45a,b in 23 and 49% two step yield, respectively. Unfortunately zwitterionic bromophenol 46 was insoluble and its transformation into the azide 18 was impossible.
For this reason we decided to perform the Huisgen cycloaddition prior HO-deprotection step in order to prepare triazole T5 (Scheme 8). Methoxymethyl protected phenol 18b was obtained in 44% yield through two steps from 44b (Scheme 6). Preparation of pyrrole boronic ester 48 from commercially available 3-bromo-N-triisopropylsilylpyrrole 47 has been performed using pinacolborane in the presence of a catalytic amount of bis(acetonitrile)palladium dichloride and S-Phos (dicyclohexyl(2 0 ,6 0 -dimethoxybiphenyl-2-yl) phosphine) [64] . The SuzukieMiyaura cross coupling [63, 65, 66] between 48 and the dihalogenated phenol 49 led only to 16% yield of biarylic compound 50 (Scheme 6). This low yield led us to consider another pathway and to perform the coupling reaction after the Click cycloaddition in order to prepare triazole T1 (Scheme 11).
The pyrimidine azide 20 was prepared through pyrimidine core construction in 41% yield over three steps. Compound 53 was obtained from condensation of benzamidine hydrochloride 51 with bketoester 52 in 56% yield according to the literature [67] (Scheme 7). Treatment of 53 in refluxing POCl 3 and PCl 5 within 3 h delivered 54 in 85% yield. Transformation of chloride 54 to azide 20 was performed using sodium azide and catalytic amount of tetra-nbutylammonium bromide (TBAB) [68] (Scheme 7).
Click reactions and preparation of target compounds
We tried to perform the synthesis of predicted 1,2,3-triazoles T2 e T7 via cycloaddition between azides 15e20 and ynamide 22a (Scheme 8). The Click chemistry concept was introduced by Sharpless and co-workers in 2001 [69, 70] . All Click reactions were performed under mild conditions using in situ prepared catalytic amount of copper(I) to control the 1,4-regioselectivity (5 mol % 4 . 5H 2 O/10 mol % sodium ascorbate) in a mixture of solvents (t-BuOH/H 2 O/CHCl 3 ) at room temperature. Deprotection of the resulting methyl carbamates 55ae59a was performed in 1 M methanolic solution of KOH to give triazoles T2, T3, T6, T7 in good yields (67e82%). Unfortunately pyrimidine triazole T4 was unstable in these conditions and only decomposition products were observed. Cycloaddition of 18b with 22a and its crude mixture deprotection resulted in a mixture of products containing the expected triazole T5 which was impossible to isolate (Scheme 8).
In order to get pyrimidine triazole T4, different conditions for deprotection of 59a have been tested (1 M KOH in MeOH or 0.5 M KOH ethylene glycol both at rt or by reflux) and gave only products of decomposition. In order to circumvent these difficulties we prepared also N-Boc protected triazole 59b by Click reaction of ynamide 22b and azide 20. Then we tried different conditions for deprotection of cycloadduct 59b (Scheme 9) and found that 12 M HCl in EA or TFA in THF led to T4 with 80 and 90% conversion [71, 72] (Scheme 9). Unfortunately, we were unable to isolate the pure triazole T4 in reasonable amounts as it was unstable on silica or alumina gel. Trituration or crystallization of the crude mixture was also unsuccessful in our hands.
Since the preparation of azide 18 failed due to the high insolubility of its precursor 46 (Scheme 6), we tried a SuzukieMiyaura coupling between triazole derivative 60 and pinacol boronic ester 35 [54] or the boronic acid 61 [73, 74] but also in these cases only insoluble material has been obtained (Scheme 10).
Finally, the triazole T1 has been prepared by the Click reaction prior to the biaryl formation (Scheme 11). The synthesis started with the preparation of the functionalized azides 65 and 68 by nitration of o-iodo phenol 62 using a 70% solution of nitric acid giving nitrophenol 63. Part of 63 was acetylated to ester 66 and a subsequent reduction of both nitro compounds 63 and 66 using SnCl 2 provided anilines 64 and 67, resp. [75] 
Inhibition of VEGFR2 TK activity
Prepared compounds T1eT3 and T6eT7 were screened on their ability to inhibit VEGFR2 kinase activity. Their IC 50 values were determined by radiometric protein kinase assay in 10 semilogarithmic concentrations [25] . Compounds T1, T3 and T7 bind specifically to VEGFR2 tyrosine kinase and resulting typical concentration dependent enzymatic activity sigmoid curves. (e.g. Fig. 9 ).
The structures of AAZ and 1,2,3-triazoles T1 e T7 together with their docking score [76] and obtained biological activity (IC 50, VEGFR2 TK) are depicted on Fig. 10 .
The compounds T1eT3, T6eT7 exhibited different inhibitory properties: from inactive compounds T2 and T6 (IC 50 > 1E-4 M), through weakly active T7, T1 (IC 50 : 42 and 40 mM, resp.) to moderately active inhibitor T3 (IC 50 : 6.96 mM). Triazole compounds T1eT3 and T6eT7 possess the same pharmacophoric 5-(ethylsulfonyl)-2-methoxyphenylamine moiety therefore the observed activities are dependent on the remaining aryltriazole fragments.
Re-docking experiments
In initially performed docking experiments (an older DOCK software) triazoles T2eT6 showed better or similar scores as their oxazole precursor AAZ (vide supra, see part 2.2 In Silico predictions). These results do not correlate well with obtained IC 50 activities determined from the biological assay. Therefore an additional docking experiment was performed with newer version of the docking software (DOCK 3.6) on more calibration reliable VEGFR2 kinase taken from PDB: 1Y6B [76] . By these conditions all triazole structures although still retaining AAZ-like pose in VEGFR2 TK, showed worse score values compared to their oxazole analogue AAZ (Figs. 10 and 11) .
A similar result, disfavouring 1,2,3-triazoles compare to oxazoles, was obtained from docking experiment of isosteric pairs derived from T1eT7 (values not shown).
Predicted VEGFR2 TK interactions of the most active 1,2,3-triazole T3 and its oxazole bioisostere T3-ox are depicted on Fig. 12 . The activity of T3-ox inhibitor (IC 50 : 12.8 nM, VEGFR2 TK) was published by us recently [77] .
Influence of isosteric oxazole/triazole replacement
The above re-docking experiment of 1,2,3-triazoles T1 e T7 resulted lower score than that obtained for their oxazole analogues. Triazoles T3 and T7 exhibit much less inhibitory activity against VEGFR2 kinase compared to their known oxazole bioisosters T3-ox and AAZ (T3/T3-ox, IC 50 : 6950 nM/12.8 nM and T7/AAZ, IC 50 : 42 400 nM/22 nM). Therefore we proposed that different electronic properties of oxazole/triazole core (the size and dipole moment orientation) could be responsible for disfavouring of 1,2,3-triazole derivatives in VEGFR2 TK AAZ binding site. The structures and dipole moments depicted on Fig. 13 were performed by Discovery Studio 3.5 Visualizer [78] .
VEGFR2 kinase surrounds the oxazole core of AAZ ligand (PDB: 1Y6A) by seven nonpolar amino acid residues: Phe916, Val914, Val897, Ala864, Leu838, Leu1033, and Cys917. This lipophilic pocket is less favourable to accommodate more polar 1,2,3-triazole ring. Therefore triazoles T1eT7 are less suitable to inhibit VEGFR2 kinase compare to their bioisosteric oxazole analogues.
Cytotoxic activity of triazoles on hepatocellular carcinoma cell lines
Four of developed 1,4-triazole compounds T1eT3 and T6 were Results indicate that three of four tested triazole molecules were able to inhibit growth of both tumour cell lines by half in indicated concentrations. (Table 1 ).
All triazoles T1eT3 and T6 display lover IC 50 values in mesenchymal-like Mahlavu cells. Even though no enzymatic modulation of T2 on VEGFR2 TK was obtained, triazole T2 is highly selective inhibitor of growth of Mahlavu cells. The mechanism of its action as possible inhibitor of PI3K/Akt pathway could be further investigated at molecular level.
Conclusions
Seven 1,2,3-triazole compounds T1eT7 derived from oxazole VEGFR2 TK inhibitor AAZ were designed. A methodology for the synthesis of the pharmacophoric ynamides 22a,b was developed. Ynamide 22a was used as a joined precursor for the synthesis of all proposed compounds T1eT7. Cu(I) catalyzed Click reaction performed from 22a with different azides (yields: 68e92 %) confirmed the synthetic reliability of this still "exotic" ynamide reagent. Five triazole compounds T1eT3, T6eT7 were prepared (Schemes 8 and 11) and screened in the radiometric VEGFR2 kinase assay. Within concentration limits of used biological test, two compounds T2, T6 showed to be inactive (IC 50 > 1E-4 M) and other three triazoles modulate VEGFR2 tyrosine kinase activity: T7 (IC 50 : 42.0 mM), T1 (IC 50 : 40.1 mM) and T3 (IC 50 : 6.96 mM). (Fig. 10) The activities of new compounds were significantly lower than the ones obtained for their oxazole bioisosters (e.g. T3/T3-ox in Fig. 12 and T7/AAZ in Fig. 10, resp. ). Despite the diminished activity, the triazole modulators T1, T3 and T7 inhibit VEGFR2 kinase by concentration dependent manner. Concerning the identical substructure, the inhibitory activity of 1,4-triazoles T1eT3, T6eT7 is depending on the decoration of their aryl part joined to N(1) of the triazole core. (Fig. 1) The different electronic properties of 1,2,3-triazole and oxazole fragments (size and orientation of the dipole moments, Fig. 13 ) were proposed to be responsible for low activities of triazoles T1eT3, T6eT7. The more polar triazole core binds less readily into VEGFR2 TK lipophilic oxazole binding pocket known Fig. 9 . An example of diminishing VEGFR2 TK activity (y axis, %) by increasing concentration of triazole T3 (x axis, logarithmic scale) and determining T3 activity (IC 50 :
6.96 mM). from PDB: 1Y6A or 1Y6B. We can conclude that the 1,2,3-triazole compounds T1, T3 and T7 are weaker VEGFR2 inhibitors than their oxazole analogues.
In addition T1eT3 and T6 were screened on their cytotoxic activity against two human hepatocellular carcinoma cell lines (Huh-7 and Mahlavu). Mahlavu is aggressive hepatocellular carcinoma with constitutive active PI3K/Akt anti-apoptotic signalling. All screened triazole compounds performed low IC 50 activity (12e28 uM) against Mahlavu cells (Table 1) . Even though compounds T6 and T2 were not active in VEGFR TK assay, both of them showed interesting cytotoxic activity against Mahlavu carcinoma. The high selectivity of triazole T2 to Mahlavu over Huh-7 cell lines indicates its possible affinity to PI3K/Akt pathway that can be further investigated.
Experimental
Molecular docking
Docking experiments were accomplished according the expert self-assessing system DOCK Blaster (University of California, San Francisco) described in the literature [79] . The calculations were performed by an older DOCK version and later on with the DOCK 3.6 version of UCSF DOCK software [33,76].
Chemistry
All reactions and compounds leading to prepared 1,2,3-triazole products T1 e T3, T6 and T7 are completely described in Supplementary Material in order as they are depicted in the Scheme 12. Beside other compound characteristics the Supplementary material contains also 1 H and 13 C NMR spectral graphical abstracts. For simplicity, only the synthetic pathway leading to the most active triazole T3 is described here (Scheme 13).
General procedures
THF and Et 2 O were dried over and distilled from Na/benzophenone under Ar atmosphere. DCM and Et 3 N were dried over calcium hydride or KOH pellets, resp. and distilled. Commercially available chemicals and solvents were purchased from SigmaeAldrich company and were used without further purification. The course of the reactions was followed by TLC analysis (Merck Silica gel 60 F 254 ). UV lamp (254 nm) and iodine vapours were used for visualization of TLC spots. Flash column chromatography was performed on silica gel (40e60 mesh). Melting points were determined on a Büchi B-540 apparatus (Büchi Labortechnik, Flawil, Switzerland) and were uncorrected. All CuSO 4 . 5H 2 O and (0.4 mol eq) 1,10-phenantroline. The reaction mixture was heated at 65e75 C (oil bath temperature) for 20 h. Upon completion, detected by TLC, the reaction mixture was cooled to RT, diluted with EA, filtered through Celite and the filtrate concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel (Scheme 3).
B: TIPS group deprotection.
A (1.0 mol eq) 1.0 M solution of TBAF in THF was added dropwise to a solution of TIPS protected ynamide (1.0 mol eq) 32aeb in dry THF. After 5 min stirring at RT, the volatile parts were evaporated under reduced pressure. The concentrated reaction mixture was partitioned in a mixture of EA and brine (1:1). Collected organic layers were dried over anhydrous MgSO 4 , filtered and evaporated leading to a desired product (Scheme 3).
4.2.1.3. C: substitution of an aromatic halide to azide. The solution of (1.0 mol eq) aryl bromide, (2.0 mol eq) NaN 3 , (0.05 mol eq) sodium ascorbate, (0.1 mol eq) CuI and (0.15 mol eq) N,N 0 -DMED in 4 mL of mixture EtOH : H 2 O (7 : 3) was refluxed under Ar atmosphere. Progress of the reaction was monitored by TLC. When the aryl bromide was completely consumed, or when the progress of the reaction had stopped, the reaction mixture was cooled to RT and the crude product purified either by extraction and/or FLC chromatography giving the desired aryl azide (Scheme 5).
D:
copper-catalyzed Click chemistry reaction. Prepared (1.0 mol eq) ynamide 22a and (1.0 mol eq) of corresponding azide were suspended in 6 mL of mixture tert-butanol : H 2 O (1 : 1) and 5 mL CHCl 3 . Consequently, premixed solution of sodium ascorbate (10 mol %) and CuSO 4 . 5H 2 O (5 mol %) in 3 mL of H 2 O was added. After stirring overnight the reaction mixture was diluted with 10 mL H 2 O and extracted with EA (3 Â 10 mL). The combined organic layers were washed with 10 mL of NH 4 OH (3% solution in brine), treated over MgSO 4 , filtered, evaporated and dried in HV. Purification using FLC chromatography afforded 1,4-disubstituted 1,2,3-triazole product (Scheme 8).
4.2.1.5. E: deprotection of methoxycarbonyl group. Protected aminotriazole derivative (2.0 mmol, 1.0 mol eq) was stirred in 5 mL of 1 M solution of KOH in MeOH at RT overnight. The progress of reaction was monitored by LCMS or 1 H NMR spectroscopy. When the reaction was accomplished, the mixture was neutralized with 1 M HCl and extracted with EA (3 Â 8 mL). The combined organic layers were washed with water, treated over MgSO 4 , filtered, evaporated under reduced pressure and dried with HV. Obtained crude product was purified by FLC (Scheme 8). (3) (4) (6) 
Synthesis of 2-(3-bromophenyl)pyridine (34)
A degassed mixture of 2.4 mL (24.9 mmol, 1.00 mol eq) 2-bromopyridine, 5.75 g (54.8 mmol, 2.20 mol eq) Na 2 CO 3 , 28 mL H 2 O, 20 mL EtOH, 63 mL 1,2-dimethoxyethane, 5.0 g (24.9 mmol, 1.00 mol eq) 3-bromophenylboronic acid (33) and 288.0 mg (0.25 mmol, 0.01 mol eq) Pd(PPh 3 ) 4 was refluxed for 18 h. The reaction mixture was filtered through a short Celite pad. Organic layer was separated and water layer extracted with EA (2 Â 35 mL). Collected organic layers were washed with water (50 mL), dried over anhydrous MgSO 4 , filtered and concentrated in vacuum. The crude product was purified by FLC column chromatography (SiO 2 , eluent: Cy/EA, 1/9) to afford 3.96 g (16.9 mmol, 68%) of 34 as colourless oil. The analytical data corresponded to the literature [82] . ) (5) 
In vitro VGEFR-2 kinase assay
A radiometric protein kinase assay ( 33 PanQinase® Activity Assay) was used for measuring the activity of VEGFR2 protein kinase. VEGFR2 tyrosine kinase was expressed in Sf9 insect cells as human recombinant GST-fusion protein. The kinase was purified by affinity chromatography using GSH-agarose. The purity of the kinase was checked by SDS-PAGE/silver staining and the identity of the kinase was verified by mass spectroscopy. IC 50 values were measured by testing 10 concentrations from 1E-4 to 1E-9 M of each compound at 1 mM ATP conc. The measurements were performed by ProQinase GmbH, Freiburg, Germany [25] . Huh7 and Mahlavu [80] , human Hepatocellular Carcinoma (HCC) cells (ATCC) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen GIBCO), with 10% fetal bovine serum (FBS) (Invitrogen GIBCO), 2 mM L-glutamine, 0.1 mM nonessential amino acids, 100 units/mL penicillin and 100 g/mL streptomycin at 37 C in a humidified incubator under 5% CO 2 . Both Huh7 and Mahlavu cells are tested their authentication by STR analysis.
NCI-60 Sulforhodamine B (SRB) cytotoxicity assay
SRB is anionic dye that can bind to proteins. The SRB assay measures the cellular protein content in order to determine cell density since cell proliferation is directly proportional to total protein synthesis [81] .
Method: Huh7 (2000 cell/well) and Mahlavu (1000 cell/well) cells were inoculated into 96 well plates (150 ml/well). 24 h later, molecules of interest and DMSO control were applied in concentrations 40 mMe2.5 mM in serial dilutions. After 72 h of treatment, cells were fixed by cold 10% (w/v) trichloroacetic acid (MERCK) for an hour. Then the wells were washed with ddH 2 O and dried. 50 ml of 0.4% SRB dye (SigmaeAldrich) was applied to each well and incubated at RT for 10 min. Then wells were washed with 1% acetic acid and left for air-drying. SRB dye was solubilized in a 100 ml 10 mM Tris-Base solution and the absorbance was measured at 515 nm. The experiment was performed in triplicates and the absorbance values were normalized to DMSO controls. Standard deviations were less than 10%.
